亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Detecting Heparin Induced Thrombocytopenia

技術優勢
Improved stability of the targets complexes and better preservation oftarget epitopes.
技術應用
Diagnosing heparin-induced thrombocytopenia.
詳細技術說明
Heparin induced thromocytopenia (HIT) and thrombosis is aserious side effect of heparin therapy cause by antibodies thatrecognize complexes consisting of heparin and platelet factor four(PF4), a platelet alpha granule protein. These patents coverdetection of HIT antibodies using1) complexes made up of PF4 and polyvinyl sulfonate (a linear polyanion) and2) PF4 complexed with heparin immobilized linked covalently at its reducing end to a solid phase.Exclusively licensed worldwide. Partnership opportunities will beforwarded to our exclusive licensee. US Patents 5,972,718 and5,972,717. Foreign country applications currently in prosecution.Heparin is given to millions of patients annually. About 5% are at risk forHIT. Any patient receiving heparin who develops unexplainedthrombocytopenia should be tested for antibody.
*Abstract
Heparin induced thromocytopenia (HIT) and thrombosis is aserious side effect of heparin therapy cause by antibodies thatrecognize complexes consisting of heparin and platelet factor four(PF4), a platelet alpha granule protein.
*Principal Investigation

Name: Benjamin Boldt

Department:


Name: Gian Visentin

Department:


Name: Manouchehr Moghaddam

Department:


Name: Richard Aster

Department:

國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備